Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 93 Show results per page	View Search Criteria \| Help With Results


1.		Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 70				Other				UARK 2003-26 NCT00090493

Last Modified: 11/11/2008 First Published: 8/1/1997


2.		Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				15 to 65				NCI				SWOG-S9704 CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11

Last Modified: 1/14/2009 First Published: 4/23/2004


3.		Phase III Randomized Study of Induction Therapy Comprising Cytarabine and Daunorubicin With Versus Without Gemtuzumab Ozogamicin Followed By Consolidation Therapy Comprising High-Dose Cytarabine and Post-Consolidation Therapy Comprising Gemtuzumab Ozogamicin Versus No Additional Therapy in Patients With Previously Untreated De Novo Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 60				NCI				SWOG-S0106 S0106, NCT00085709

Last Modified: 11/29/2008 First Published: 3/22/2007


4.		Phase III Randomized Study of PR1 Leukemia Peptide Vaccine and Sargramostim (GM-CSF) in Patients With Acute Myeloid Leukemia in Remission

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				VACCINE-PR1-104 UCCRC-14613B, NCT00454168

Last Modified: 12/2/2008 First Published: 1/16/2007


5.		Phase III Randomized Study of Chemoimmunotherapy Comprising Gemcitabine Hydrochloride and Capecitabine With or Without Telomerase Peptide Vaccine GV1001 in Patients With Locally Advanced or Metastatic Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Over 18				Other				CRUK-TELOVAC-V4 EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC


6.		Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				005/05 NCT00769704

Last Modified: 8/23/2008 First Published: 12/1/2001


7.		Phase I/II Study of Immunotherapy With Armed Activated T Cells, Interleukin-2, and Sargramostim (GM-CSF) in Women With Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Other				WSU-2006-130 NCT00027807, RWMC-0635146, WSU-010307M1F, WSU-0312004412

Last Modified: 12/23/2008 First Published: 12/21/2002


8.		Phase I/II Study of Vaccinia-CEA-TRICOM Vaccine Before Dose-Intensive Induction Chemotherapy and Fowlpox-CEA-TRICOM Vaccine After Dose-Intensive Induction Chemotherapy and Immune Depletion in Patients With Previously Untreated Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NCI-03-C-0040 NCI-5762, 03-C-0040, NCT00053170

First Published: 10/12/2007


9.		Phase I/II Study of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone Hydrochloride in Patients With Previously Treated Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MSKCC-05077 MSKCC IRB PRotocol #05-077, NCT00546377


10.		Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Other				04-117 NCT00458536

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute